Risk/benefit considerations

What we know vs. what we don’t know

• Existing systemic treatments for psoriasis have serious known long-term risks, or are limited in efficacy

• Many patients and physicians are willing to accept unknown long-term risks of biologic therapy 

Previous slide

Next slide

Back to first slide

View graphic version